CytomX Therapeutics, Inc. — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/dc5d13e7-3923-4713-88c0-a80148751b73/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-22.4M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-107146 |
| FY 2024 | $25.0M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-034575 |
| FY 2023 | $-6.5M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-029191 |
| FY 2022 | $-101.3M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-009991 |
| FY 2021 | $-116.0M | 2021-01-01 – 2021-12-31 | evidence 0000950170-23-009984 |
| FY 2020 | $-80.5M | 2020-01-01 – 2020-12-31 | evidence 0000950170-23-009984 |
| FY 2019 | $-141.5M | 2019-01-01 – 2019-12-31 | evidence 0000950170-23-009984 |
| FY 2018 | $-77.9M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-004890 |
| FY 2017 | $-46.3M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004727 |
| FY 2016 | $-59.6M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-003229 |
| FY 2015 | $-33.2M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014091 |
| FY 2014 | $-29.8M | 2014-01-01 – 2014-12-31 | evidence 0001564590-16-014091 |
| FY 2013 | $-15.0M | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-014091 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CytomX Therapeutics, Inc. — all facts · Revenue · Net Income